Effect of adjuvant trastuzumab treatment in conventional clinical setting: An observational retrospective multicenter Italian study

Breast Cancer Research and Treatment

Volumn 141, Issue 1, 2013, Pages 101-110

  Campiglio, M ^a   Bufalino, R ^a   Sasso, M ^a   Ferri, E ^a   Casalini, P ^a   Adamo, V ^b   Fabi, A ^c   Aiello, R ^d   Riccardi, F ^e   Valle, E ^f   Scotti, V ^g   Tabaro, G ^h   Giuffrida, D ⁱ   Tarenzi, E ^j   Bologna, A ^k   Mustacchi, G ^l   Bianchi, F ^a   Balsari, A ^m   Menard S ^a   Tagliabue, E ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITY OF PALERMO   (Italy)

^c REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^d Humanitas Centro Catanese di Oncologia   (Italy)

^e CARDARELLI HOSPITAL   (Italy)

^f Ospedale Oncologico A Businco   (Italy)

^g CAREGGI UNIVERSITY HOSPITAL   (Italy)

^h Centro Oncologico Aviano   (Italy)

ⁱ Istituto Oncologico del Mediterraneo   (Italy)

^j Dipartimento Oncologico dell'Ospedalie Niguarda Ca' Granda   (Italy)

^k S MARIA NUOVA HOSPITAL   (Italy)

^l UNIVERSITY OF TRIESTE   (Italy)

^m UNIVERSITY OF MILAN   (Italy)

more..

Author keywords

Adjuvant therapy; Breast cancer; Distant metastasis; HER2; Trastuzumab

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; TRASTUZUMAB;

ADULT; ARTICLE; BONE METASTASIS; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER INFILTRATION; CANCER PROGNOSIS; CANCER STAGING; CARDIOTOXICITY; CONGESTIVE HEART FAILURE; DISEASE FREE SURVIVAL; DISTANT METASTASIS; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GASTROINTESTINAL DISEASE; HEART LEFT VENTRICLE EJECTION FRACTION; HEMATOLOGIC DISEASE; HER2 GENE; HUMAN; INFECTION; ITALY; KIDNEY DISEASE; LIVER DISEASE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; NEUROLOGIC DISEASE; OBSERVATIONAL STUDY; PATIENT COMPLIANCE; PRIORITY JOURNAL; RESPIRATORY TRACT DISEASE; RETROSPECTIVE STUDY; SIDE EFFECT; SKIN DISEASE; TUMOR INVASION; TUMOR RECURRENCE;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CARCINOMA; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; GENES, ERBB-2; HEART DISEASES; HUMANS; ITALY; MEDICATION ADHERENCE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASM PROTEINS; NEOPLASM STAGING; PROGNOSIS; RECEPTOR, ERBB-2; RETROSPECTIVE STUDIES; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 84884288034     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-013-2658-z     Document Type: Article

References (30)

1. Slamon DJ, Clark GM, Wong SG et al (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177-182
2. Slamon DJ, Godolphin W, Jones LA et al (1989) Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244:707-712
3. Reese DM, Slamon DJ (1997) HER-2/neu signal transduction in human breast and ovarian cancer. Stem Cells 15:1-8
4. Tagliabue E, Campiglio M, Pupa SM et al (2012) Activity and resistance mechanisms of trastuzumab in different clinical settings. Cancer Treat Rev 38:212-217
5. Carter P, Presta L, Gorman CM et al (1992) Humanization of an anti-p185 HER2 antibody for human cancer therapy. Proc Natl Acad Sci USA 89:4285-4289
6. Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al (2005) Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353:1659-1672
7. Romond EH, Perez EA, Bryant J et al (2005) Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353:1673-1684
8. Joensuu H, Bono P, Kataja V et al (2009) Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial. J Clin Oncol 27:5685-5692
9. Slamon D, Eiermann W, Robert N et al (2011) Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 365:1273-1283
10. Smith I, Procter M, Gelber RD et al (2007) 2-Year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 369:29-36
11. Gianni L, Dafni U, Gelber RD et al (2011) Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial. Lancet Oncol 12:236-244
12. Goldhirsch A, Piccart-Gebhart MJ, Procter (2013) HERA TRIAL: 2 years versus 1 year of trastuzumab after adjuvant chemotherapy in women with HER2-positive early breast cancer at 8 years of median follow up. Cancer Res 72 [24 suppl], 103 s (S5-2)
13. Cox DR (1972) Regression models and life tables. J R Stat Soc 34:187-220
14. Suter TM, Procter M, van Veldhuisen DJ et al (2007) Trastuzumab- associated cardiac adverse effects in the herceptin adjuvant trial. J Clin Oncol 25:3859-3865
15. Procter M, Suter TM, De AE et al (2010) Longer-term assessment of trastuzumab-related cardiac adverse events in the Herceptin Adjuvant (HERA) trial. J Clin Oncol 28:3422-3428
16. Bowles EJ, Wellman R, Feigelson HS et al (2012) Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study. J Natl Cancer Inst 104:1293-1305
17. Palmieri C, Shah D, Krell J et al (2011) Management and outcome of HER2-positive early breast cancer treated with or without trastuzumab in the adjuvant trastuzumab era. Clin Breast Cancer 11:93-102
18. Sharma SV, Settleman J (2007) Oncogene addiction: setting the stage for molecularly targeted cancer therapy. Genes Dev 21:3214-3231
19. Kennecke H, Yerushalmi R, Woods R et al (2010) Metastatic behavior of breast cancer subtypes. J Clin Oncol 28:3271-3277
20. Hasan A, Ghebeh H, Lehe C et al (2011) Therapeutic targeting of B7-H1 in breast cancer. Expert Opin Ther Targets 15:1211-1225
21. Geyer CE, Martin A, Newstat B, et al. (2007) Lapatinib (L) plus capecitabine (C) in HER2+ advanced breast cancer (ABC): Genomic and updated efficacy data. J Clin Oncol. Suppl 25, 40s-Abstract 1035
22. Azim HA, Azim HA Jr (2012) Systemic treatment of brain metastases in HER2-positive breast cancer: current status and future directions. Future Oncol 8:135-144
23. Dijkers EC, Oude Munnink TH, Kosterink JG et al (2010) Biodistribution of 89Zr-trastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer. Clin Pharmacol Ther 87:586-592
24. Niikura N, Liu J, Hayashi N et al (2012) Loss of human epidermal growth factor receptor 2 (HER2) expression in metastatic sites of HER2-overexpressing primary breast tumors. J Clin Oncol 30:593-599
25. Johnston SR, Head J, Pancholi S et al (2003) Integration of signal transduction inhibitors with endocrine therapy: an approach to overcoming hormone resistance in breast cancer. Clin Cancer Res 9:524S-532S
26. Rosales C, Brown EJ (1991) Two mechanisms for IgG Fc-receptor-mediated phagocytosis by human neutrophils. J Immunol 146:3937-3944
27. Jones DH, Nakashima T, Sanchez OH et al (2006) Regulation of cancer cell migration and bone metastasis by RANKL. Nature 440:692-696
28. Metzger-Filho O, Procter M, De Azambuja AE et al (2013) Magnitude of trastuzumab benefit in patients with HER2-positive, invasive lobular breast carcinoma: results from the HERA trial. J Clin Oncol 31:1954-1960
29. Spielmann M, Roche H, Delozier T et al (2009) Trastuzumab for patients with axillary-node-positive breast cancer: results of the FNCLCC-PACS 04 trial. J Clin Oncol 27(36):6129-6134
30. Blackwell KL, Burstein HJ, Storniolo AM et al (2012) Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study. J Clin Oncol 30(21):2585-2592